Cell-intrinsic PD-L1 ablation sustains effector CD8+ T cell responses and promotes antitumor T cell therapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Cell-intrinsic PD-L1 ablation sustains effector CD8+ T cell responses and promotes antitumor T cell therapy

Published:2024-02 Issue:2 Volume:43 Page:113712
ISSN:2211-1247
Container-title:Cell Reports
language:en
Short-container-title:Cell Reports

Author:

Wang Xinran,Lu Lu,Hong Xiaochuan,Wu Lingling,Yang Chao,Wang You,Li Wenwen,Yang Yuanqin,Cao Dongqing,Di Wen,Deng Liufu^ORCID

Funder

National Key Research and Development Program of China Stem Cell and Translational Research

Thousand Young Talents Program of China

National Natural Science Foundation of China

Science and Technology Commission of Shanghai Municipality

National Key Research and Development Program of China

Shanghai Jiao Tong University

Publisher

Elsevier BV

Reference45 articles.

1. A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization;Sanmamed;Cell,2018

2. Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy;Sharma;Cell,2017

3. Top 10 Challenges in Cancer Immunotherapy;Hegde;Immunity,2020

4. Acquired Resistance to Immune Checkpoint Inhibitors;Schoenfeld;Cancer Cell,2020

5. The diverse functions of the PD1 inhibitory pathway;Sharpe;Nat. Rev. Immunol.,2018

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP